Telix Pharmaceuticals (Telix Pharmaceuticals) Ending Cash Position : $82.5 Mil (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Telix Pharmaceuticals Ending Cash Position?

Telix Pharmaceuticals's Ending Cash Position for the quarter that ended in Dec. 2023 was $82.5 Mil.

Telix Pharmaceuticals's quarterly Ending Cash Position increased from Dec. 2022 ($78.5 Mil) to Jun. 2023 ($88.4 Mil) but then declined from Jun. 2023 ($88.4 Mil) to Dec. 2023 ($82.5 Mil).

Telix Pharmaceuticals's annual Ending Cash Position increased from Dec. 2021 ($15.8 Mil) to Dec. 2022 ($78.5 Mil) and increased from Dec. 2022 ($78.5 Mil) to Dec. 2023 ($82.5 Mil).

Telix Pharmaceuticals Ending Cash Position Historical Data

The historical data trend for Telix Pharmaceuticals's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telix Pharmaceuticals Ending Cash Position Chart

Telix Pharmaceuticals Annual Data

Trend

Sep99

Sep00

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Ending Cash Position

Get a 7-Day Free Trial

30.72

58.69

15.76

78.50

82.49

Telix Pharmaceuticals Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Ending Cash Position	Get a 7-Day Free Trial								15.76	86.16	78.50	88.41	82.49

Telix Pharmaceuticals Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Telix Pharmaceuticals's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	77.864	+	4.624
	=	82.5

Telix Pharmaceuticals's Ending Cash Position for the quarter that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	88.172	+	-5.684
	=	82.5

Telix Pharmaceuticals Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Telix Pharmaceuticals's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Telix Pharmaceuticals (Telix Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Telix Pharmaceuticals Ltd (OTCPK:TLPPF) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

TLX:Australia

Address

55 Flemington Road, Suite 401, North Melbourne, Melbourne, VIC, AUS, 3051

Website

https://www.telixpharma.com

Telix Pharmaceuticals Ltd is a clinical-stage biotechnology company engaged in developing and commercializing molecularly-targeted radiation therapy to address the unmet needs in the management of prostate, renal (kidney) and glioblastoma (brain) cancer. Geographically, it operates in Australia, the United States, Belgium, and Japan.